Pfizer’s palbociclib most commonly used breast cancer drug in clinical trials
Pfizer’s palbociclib is the most commonly used breast cancer drug in clinical trials, according to analytics firm GlobalData.
The drug, which was used in 4% of breast cancer clinical trials conducted in 2018, was investigated for its use as a combination therapy in the vast majority of cases.
Mohamed Abukar, Pharma Analyst at GlobalData, commented: “The vast majority of trials investigating palbociclib use combination therapy (83%) to assess progression-free survival. The tubulin inhibitor paclitaxel was investigated in 3.5% of clinical trials, primarily in combination regimens; only 6.3% of clinical trials investigate the agent as monotherapy, and involved comparing different routes of administration.”
Meanwhile 10.9% of all oncology trials were related to breast cancer between 1 January 2018 and 16 November 2018.
Overall, the majority of clinical trials were in Phase II (50.8%) while the US led in regards to the quantity of clinical trials they conducted with 22.4% of trials being done in United States. In comparison China, who came in second place, conducted 10.6% of clinical trials.
Eli Lilly and POINT Biopharma have announced a definitive agreement for Lilly to acquire POINT …
The US Food and Drug Administration (FDA) has granted de novo marketing authorisation to the …